The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kurysheva N.I.

Oftal'mologicheskij tsentr Federal'nogo mediko-biologicheskogo agentstva, ul. Gamalei, 15, Moskva, Rossijskaja Federatsija, 123098

Long-term use of latanoprost in the treatment of glaucoma

Authors:

Kurysheva N.I.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(2): 125‑132

DOI: 10.17116/oftalma2020136021125

Views: 10128

Downloaded: 177

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kurysheva NI. Long-term use of latanoprost in the treatment of glaucoma. Russian Annals of Ophthalmology. 2020;136(2):125‑132. (In Russ.)
https://doi.org/10.17116/oftalma2020136021125

Подписка 2025 (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Clinical outcomes of laser acti­vation of hydraulic permeability of the sclera in the treatment of adva­nced glaucoma. Russian Annals of Ophthalmology. 2023;(6):19-25
Problem and factors of patients with chro­nic heart failure treatment compliance acco­rding to outpatient regi­stry. Russian Journal of Preventive Medi­cine. 2023;(11):39-44
The effect of mexi­dol as part of complex therapy on the perception of life in patients with heart failure. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;(6):642-652
Quality of life and functional status of patients after auto­logous peri­cardial aortic valve reco­nstruction. Russian Cardiology Bulletin. 2023;(4):67-75
Life­style of patients with non-alcoholic fatty liver disease: asse­ssment of dietary habits and physical acti­vity. Russian Journal of Evidence-Based Gastroenterology. 2023;(4):43-53
Asse­ssment of eating habits, psycho-emotional state, quality of life and risk factors for the deve­lopment of gestational diabetes mellitus in women with threatened late miscarriage. Russian Bulletin of Obstetrician-Gynecologist. 2023;(6-2):155-161
Study of the effe­ctiveness of shampoo application (combination of 3% sali­cylic acid, piro­ctone olamine and panthenol) as an exte­rnal therapy of scalp psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2023;(6):708-714
Comprehensive solu­tion of acne and postacne problem. Russian Journal of Clinical Dermatology and Vene­reology. 2023;(6):741-748
The impact of therapy with Mexi­dol on neurological defi­cit and functional outcome in patients with ischemic stroke: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(12-2):49-60
High-tone therapy in complex reha­bilitation of patients with post-sternotomy syndrome after coro­nary artery bypass surgery. (Open-label, prospective, randomized controlled trial). Problems of Balneology, Physiotherapy and Exercise Therapy. 2023;(6):14-20

Glaucoma is the main cause of irreversible blindness in the world. Latanoprost — an ester prodrug of prostaglandin F2α (PGF2α) — was the first prostaglandin analogue used in the treatment of glaucoma. The present review shows that latanoprost is the most balanced prostaglandin analogue in terms of efficacy—safety. Its use improves the quality of life of glaucoma patients, provides reliable IOP reduction, has high patient compliance, and helps with the long-term preservation of visual functions. The review also reveals the possibility of long-term (more than five years) use of the drug, as well as effective combined treatment using latanoprost and beta-blockers, considers the pediatric use of latanoprost, and discusses its neuroprotective properties.

Keywords:

prostaglandin analogue F2α (PGF2α)
glaucoma
glaucoma progression
24-hour IOP control
treatment adherence
quality of life
neuroprotection

Authors:

Kurysheva N.I.

Oftal'mologicheskij tsentr Federal'nogo mediko-biologicheskogo agentstva, ul. Gamalei, 15, Moskva, Rossijskaja Federatsija, 123098

List of references:

  1. Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367-1377. https://doi.org/10.1016/S0140-6736(10)61423-7
  2. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013
  3. Guidelines for Glaucoma Eye Care [PDF]. International Council of Ophthalmology. 2016. Accessed February 4, 2020. https://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf
  4. Terminology and Guidelines for Glaucoma [internet pages]. European Glaucoma Society. 2014. Accessed February 4, 2020. http://www.eugs.org/eng/guidelines.asp
  5. Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129-140. https://doi.org/10.1016/j.ophtha.2015.09.005
  6. Prum BE, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern Guidelines. Ophthalmology. 2016;123(1):41-111. https://doi.org/10.1016/j.ophtha.2015.10.053
  7. Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13(5):723-745. https://doi.org/10.1517/14656566.2012.662219
  8. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropyl ester in the cynomolgus monkey. Exp Eye Research. 1989;48:707-716. https://doi.org/10.1016/0014-4835(89)90011-0
  9. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Investigative Ophthalmology & Visual Science. 2002;43:716-722.
  10. Sagara T, Gaton DD, Lindsey JD, Gabelt B’AT, Kaufman PL, Weinreb RN. Topical prostaglandin F2 α treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:794-801. https://doi.org/10.1001/archopht.117.6.794
  11. Konstas A, Koliakos G, Kanhardt as C, Liakos P, Schlotzer-Schrehaedt U, Ritch R. Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humor of patients with exfoliative glaucoma. Experimental Eye Research. 2006;82(2):319-322. https://doi.org/10.1016/j.exer.2005.07.004
  12. Kurysheva NI. The new advantages and perspectives of Latanoprost (Xalatan, Pfizer, USA) treatment in pseudoexfoliation glaucoma. Oftal’mologicheskie vedomosti. 2013;6(1):61-65. (In Russ.). https://doi.org/10.17816/ov2013161-65
  13. Konstas A, Kozobolis V. Efficacy and safety of latanoprost versus travaprost in exfoliative glaucoma patients. Ophthalmology. 2007;114(4):653-657. https://doi.org/10.1016/j.ophtha.2006.07.064
  14. Tam ALC, Gupta N, Zhang Z, Yücel YH. Latanoprost stimulates ocular lymphatic drainage: an in vivo nanotracer study. Translational Vision Science & Technology. 2013;2(5):3. https://doi.org/10.1167/tvst.2.5.3
  15. Yücel YH, Johnston MG, Ly T, Patel M, Drake B, Gümüş E, et al. Identification of lymphatics in the ciliary body of the human eye: A novel «uveolymphatic» outflow pathway. Experimental Eye Research. 2009;89(5):810-819. https://doi.org/10.1016/j.exer.2009.08.010
  16. Alm A, Stjernschantz J. Effects on Intraocular Pressure and Side Effects of 0.005% Latanoprost Applied Once Daily, Evening or Morning. Ophthalmology. 1995;102(12):1743-1752. https://doi.org/10.1016/s0161-6420(95)30798-1
  17. Koroev OA, Khadikova EV, Koroev AO, et al. The hypotensive effect of topical prostaglandin application with respect to involutional changes of the anterior portion of the uveal tract. Rossiiskii oftal’mologicheskii zhurnal. 2016;9(2):38-41. (In Russ.). https://doi.org/10.21516/2072-0076-2016-9-2-38-41
  18. Alm A, Widengard I, Kjellgren D, Soderstrom M, Fristrom B, Heijl A, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. British Journal of Ophthalmology. 1995;79(1):12-16. https://doi.org/10.1136/bjo.79.1.12
  19. O’Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. British Journal of Ophthalmology. 2000;84(6):579-582. https://doi.org/10.1136/bjo.84.6.579
  20. Alm A. A 5-Year, Multicenter, Open-Label, Safety Study of Adjunctive Latanoprost Therapy for Glaucoma. Archives of Ophthalmology. 2004;122(7):957. https://doi.org/10.1001/archopht.122.7.957
  21. Kurysheva NI, Khodak NA, Trubilin VN. The study of the neuroprotective activity of Xalatan in a clinic. Glaukoma. 2008;2:35-40. (In Russ.).
  22. Ryabtseva AA, Khomyakova EN, Sergushev SG. Monitoring of xalatan hypotensive effect in patients with POAG and myopia. Klinicheskaya Oftal’mologiya. 2008;3:110. (In Russ.).
  23. Kara C, Şen EM, Elgin KU, Serdar K, Yilmazbaş P. Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term? International Ophthalmology. 2016;37(3):619-626. https://doi.org/10.1007/s10792-016-0315-3
  24. Ikeda Y, Mori K, Tada K, Ueno M, Kinoshita S, Sotozono C. Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma. Clinical Ophthalmology. 2016;8(10):1633-1637. https://doi.org/10.2147/opth.s108213
  25. Fogagnolo P, Dipinto A, Vanzulli E, Maggiolo E, De Cilla’ S, Autelitano A, et al. A 1-Year Randomized Study of the Clinical and Confocal Effects of Tafluprost and Latanoprost in Newly Diagnosed Glaucoma Patients. Advances in Therapy. 2015;32(4):356-369. https://doi.org/10.1007/s12325-015-0205-5
  26. Birt CM, Buys YM, Ahmed II, Trope GE. Prostaglandin Efficacy and Safety Study Undertaken by Race (The PRESSURE Study). Journal of Glaucoma. 2010;19(7):460-467. https://doi.org/10.1097/ijg.0b013e3181c4aeac
  27. Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma. Ophthalmology. 2016;123(1):129-140. https://doi.org/10.1016/j.ophtha.2015.09.005
  28. Mishra D, Sinha BP, Kumar MS. Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma. Korean Journal of Ophthalmology. 2014;28(5):399. https://doi.org/10.3341/kjo.2014.28.5.399
  29. Lin L, Zhao YJ, Chew PTK, Sng CCA, Wong H-T, Yip LW, et al. Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy. 2014;48(12):1585-1593. https://doi.org/10.1177/1060028014548569
  30. Chen R, Yang K, Zheng Z, Ong M-L, Wang N-L, Zhan S-Y. Meta-analysis of the Efficacy and Safety of Latanoprost Monotherapy in Patients With Angle-closure Glaucoma. Journal of Glaucoma. 2016;25(3):134-144. https://doi.org/10.1097/ijg.0000000000000158
  31. Zhukova OV, Zolotarev AV. Effect of latanoprost in various types of glaucoma and ocular hypertemsion in children. Russkii meditsinskii zhurnal. 2014;4:10-14. (In Russ.).
  32. Younus M, Schachar RA, Zhang M, Sultan MB, Tressler CS, Huang K, et al. A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study. American Journal of Ophthalmology. 2018;196:101-111. https://doi.org/10.1016/j.ajo.2018.08.039
  33. Black AC, Jones S, Yanovitch TL, Enyedi LB, Stinnett SS, Freedman SF. Latanoprost in pediatric glaucoma — pediatric exposure over a decade. Journal of American Association for Pediatric Ophthalmology and Strabismus. 2009;13(6):558-562. https://doi.org/10.1016/j.jaapos.2009.10.003
  34. Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. The Lancet. 2015;385(9975):1295-1304. https://doi.org/10.1016/s0140-6736(14)62111-5
  35. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of Long-term Progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114(11):1965-1972. https://doi.org/10.1016/j.ophtha.2007.03.016
  36. Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Böhres A, Appleton P. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study. Arch Ophthalmol. 2001;119:191-196.
  37. Gaddie IB, Bennett DW. Cystoid macula edema associated with the use of latanoprost. J Am Optom Assoc. 1998;69:122-128.
  38. Hernstadt DJ, Husain R. Effect of prostaglandin analogue use on the development of cystoid macular edema after phacoemulsification using STROBE statement methodology. Journal of Cataract and Refractive. 2017;43(4):564-569. https://doi.org/10.1016/j.jcrs.2017.03.005
  39. Selen F, Tekeli O, Yanık Ö. Assessment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs. Journal of Ocular Pharmacology and Therapeutics. 2017;33(3):170-175. https://doi.org/10.1089/jop.2016.0128
  40. Kurysheva NI, Polunina EV, Ardzhukhanov DD, Tkhamodakova AM. Impact of tafluprost and tafluprost/timolol on the thickness of the retina in the macular area. Rossiiskii oftal’mologicheskii zhurnal. 2019;12(1):18-24. (In Russ.). https://doi.org/10.21516/2072-0076-2019-12-1-18-24
  41. Kurysheva N. Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination. Taiwan Journal of Ophthalmology. 2019;9(2):93. https://doi.org/10.4103/tjo.tjo_108_17
  42. Ge J, Li X, Sun X, et al. Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution). Zhonghua Yan Ke Za Zhi. 2015;51(2):95-102.
  43. Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2016;254(6):1151-1158. https://doi.org/10.1007/s00417-016-3299-9
  44. Lin L, Zhao YJ, Chew PTK, Sng CCA, Wong H-T, Yip LW, et al. Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy. 2014;48(12):1585-1593. https://doi.org/10.1177/1060028014548569
  45. Rouland J-F, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. British Journal of Ophthalmology. 2012;97(2):196-200. https://doi.org/10.1136/bjophthalmol-2012-302121
  46. Stolz J, Alm A. Latanoprost in the treatment of glaucoma. Clinical Ophthalmology. 2014;1967-1985. https://doi.org/10.2147/opth.s59162
  47. Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, et al. Prostaglandin Analogs and Timolol-Fixed Versus Unfixed Combinations or Monotherapy for Open-Angle Glaucoma: A Systematic Review and Meta-Analysis. Journal of Ocular Pharmacology and Therapeutics. 2013;29(4):382-389. https://doi.org/10.1089/jop.2012.0186
  48. Inoue K, Masumoto M, Higa R, Wakakura M, Kohmoto H, Kei Noguchi, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clinical Ophthalmology. 2012;771-775. https://doi.org/10.2147/opth.s31085
  49. Palmberg P, Kim EE, Kwok KK, Tressler CS. A 12-Week, Randomized, Double-Masked Study of Fixed Combination Latanoprost/Timolol versus Latanoprost or Timolol Monotherapy. European Journal of Ophthalmology. 2010;20(4):708-718. https://doi.org/10.1177/112067211002000411
  50. Liu AW, Gan LY, Yao X, et al. Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy. International Journal of Ophthalmology. 2016;9(5):750-756. https://doi.org/10.18240/ijo.2016.05.21
  51. Xing Y, Jiang FG, Li T. Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. International Journal of Ophthalmology. 2014;7(5):879-890.
  52. Lou H, Wang H, Zong Y, Cheng J-W, Wei R-L. Efficacy and tolerability of prostaglandin — timolol fixed combinations: an updated systematic review and meta-analysis. Current Medical Research and Opinion. 2015;31(6):1139-1147. https://doi.org/10.1185/03007995.2015.1039504
  53. Cheng J-W, Cheng S-W, Gao L-D, Lu G-C, Wei R-L. Intraocular Pressure-Lowering Effects of Commonly Used Fixed-Combination Drugs with Timolol: A Systematic Review and Meta-Analysis. PLoS ONE. 2012;7(9):e45079. https://doi.org/10.1371/journal.pone.0045079
  54. Inoue K, Okayama R, Higa R, Sawada H, Wakakura M, Tomita G. Ocular Hypotensive Effects and Safety over 3 Months of Switching from an Unfixed Combination to Latanoprost 0.005%/Timolol Maleate 0.5% Fixed Combination. Journal of Ocular Pharmacology and Therapeutics. 2011;27(6):581-587. https://doi.org/10.1089/jop.2011.0057
  55. Konstas AGP, Quaranta L, Bozkurt B, Katsanos A, Garcia-Feijoo J, Rossetti L, et al. 24-h Efficacy of Glaucoma Treatment Options. Advances in Therapy. 2016;33(4):481-517. https://doi.org/10.1007/s12325-016-0316-7
  56. Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, et al. Effects of Topical Hypotensive Drugs on Circadian IOP, Blood Pressure, and Calculated Diastolic Ocular Perfusion Pressure in Patients with Glaucoma. Investigative Opthalmology & Visual Science. 2006;47(7):2917-2923. https://doi.org/10.1167/iovs.05-1253
  57. Liu CJ-L, Ko Y-C, Cheng C-Y, Chou JC, Hsu W-M, Liu J-H. Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. British Journal of Ophthalmologу. 2002;86(11):1236-1239. https://doi.org/10.1136/bjo.86.11.1236
  58. Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmologica Scandinavica. 2007;85(8):838-843. https://doi.org/10.1111/j.1600-0420.2007.00960.x
  59. Quaranta L, Pizzolante T, Riva I, Haidich A-B, Konstas AGP, Stewart WC. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. British Journal of Ophthalmology. 2008;92(9):1227-1231. https://doi.org/10.1136/bjo.2008.138024
  60. Schwartz GF, Tan J, Kotak S. Hyperemia-Associated Costs of Medication Changes in Glaucoma Patients Treated Initially With Prostaglandin Analogs. Journal of Ocular Pharmacology and Therapeutics. 2009;25(6):555-562. https://doi.org/10.1089/jop.2009.0057
  61. Orme M, Collins S, Dakin H, Kelly S, Loftus J. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Current Medical Research and Opinion. 2009;26(3):511-528. https://doi.org/10.1185/03007990903498786
  62. Kurysheva NI, Shatalova EO, Lepeshkina LV. Predictors of glaucoma progression. Nauchno-prakticheskii zhurnal po oftal’mologii «Vostok—Zapad. Tochka zreniya». 2018;(3):7-10. (In Russ.). https://doi.org/10.25276/2410-1257-2018-7-10
  63. Paletta Guedes P, Guedes RAP, Freitas, Chaoubah. Quality of life of glaucoma patients under medical therapy with different prostaglandins. Clinical Ophthalmology. 2012;6:1749-1753. https://doi.org/10.2147/opth.s37347
  64. Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Experimental Eye Research. 2011;93(3):265-270. https://doi.org/10.1016/j.exer.2011.06.022
  65. Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Experimental Eye Research. 2009;88(3):535-541. https://doi.org/10.1016/j.exer.2008.11.012
  66. Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V. Latanoprost Exerts Neuroprotective Activity in vitro and in vivo. Experimental Eye Research. 2001;72(4):479-486. https://doi.org/10.1006/exer.2000.0975
  67. McCullough L. Neuroprotective Function of the PGE2 EP2 Receptor in Cerebral Ischemia. Journal of Neuroscience. 2004;24(1):257-268. https://doi.org/10.1523/jneurosci.4485-03.2004
  68. Odani N, Seike H, Kurashima H. Protective effect of latanoprost on glutamate-induced cytotoxicity. World Glaucoma Congress. Singapore; 2007;184-185.
  69. Kudo H, Nakazawa T. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2007;3:15-19. https://doi.org/10.1007/s00417-005-0215-0
  70. Kokkinaki M, Abu-Asab M, Gunawardena N, Ahern G, Javidnia M, Young J, et al. Klotho Regulates Retinal Pigment Epithelial Functions and Protects Against Oxidative Stress. Journal of Neuroscience. 2013;33(41):16346-16359. https://doi.org/10.1523/jneurosci.0402-13.2013
  71. Yamamoto K, Sato K, Yukita M, Yasuda M, Omodaka K, Ryu M, et al. The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. Journal of Neurochemistry. 2016;140(3):495-508. https://doi.org/10.1111/jnc.13902
  72. Kurysheva NI, Azizova OA, Piryazev AP. A Comparative Study into Antioxidant Activity of Fixed Combinations in Topical Glaucoma Treatment. Rossiiskii oftal’mologicheskii zhurnal. 2013;2(6):41-44. (In Russ.).
  73. Fuma S, Shimazawa M, Imamura T, Kanno Y, Takano N, Tsuruma K, et al. Neuroprotective Effect of Ocular Hypotensive Drugs: Latanoprost/Timolol in Combination Are More Effective than Each as Monotherapy in RGC-5. Biological and Pharmaceutical Bulletin. 2016;39(2):192-198. https://doi.org/10.1248/bpb.b15-00584

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.